cloudymist6
About
Final results in order to first-line pembrolizumab in patients along with PD-L1-high (≥50%) non-small cellular cancer of the lung as well as a poor functionality standing.
Final results in order to first-line pembrolizumab in patients along with PD-L1-high (≥50%) non-small cellular cancer of the lung as well as a poor functionality standing.